19,978 Shares in RxSight, Inc. (NASDAQ:RXST) Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC bought a new position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,978 shares of the company's stock, valued at approximately $988,000. Los Angeles Capital Management LLC owned approximately 0.05% of RxSight at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the business. CWM LLC grew its stake in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company's stock worth $25,000 after purchasing an additional 371 shares during the period. Nisa Investment Advisors LLC grew its stake in RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company's stock valued at $29,000 after acquiring an additional 521 shares during the last quarter. Quest Partners LLC purchased a new position in RxSight during the 2nd quarter valued at about $41,000. Amalgamated Bank raised its position in RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company's stock worth $71,000 after acquiring an additional 207 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of RxSight in the second quarter valued at approximately $156,000. 78.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on RXST shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Wells Fargo & Company cut their price objective on shares of RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. Jefferies Financial Group initiated coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a "buy" rating and a $72.00 target price on the stock. Stifel Nicolaus lowered their target price on shares of RxSight from $70.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, August 6th. Finally, Oppenheimer decreased their price objective on RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, RxSight currently has an average rating of "Buy" and a consensus target price of $61.63.

RxSight Trading Up 2.0 %

NASDAQ:RXST traded up $0.89 on Friday, hitting $45.05. 668,980 shares of the stock were exchanged, compared to its average volume of 490,411. RxSight, Inc. has a fifty-two week low of $27.07 and a fifty-two week high of $66.54. The stock has a fifty day moving average of $50.32 and a 200-day moving average of $53.27. The stock has a market cap of $1.82 billion, a PE ratio of -54.28 and a beta of 1.19.

Insider Buying and Selling

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00. Following the sale, the insider now directly owns 42,246 shares in the company, valued at $2,225,096.82. The trade was a 6.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jesse Anderson Corley bought 11,111 shares of RxSight stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average price of $45.37 per share, with a total value of $504,106.07. Following the completion of the purchase, the director now owns 468,571 shares in the company, valued at approximately $21,259,066.27. The trade was a 2.43 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 44,745 shares of company stock valued at $2,240,200. Company insiders own 9.36% of the company's stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.